Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

ATLANTA, Dec. 8 /PRNewswire/ -- UCB today announced new findings from analyses of pooled Vimpat(R) (lacosamide) clinical trial data, demonstrating that the new antiepileptic drug (AED) starts working during the first week of treatment and across doses in a challenging patient population, when administered as adjunctive therapy. The analyses also showed that Vimpat(R) provides consistent seizure reduction versus placebo, when added to concomitant AEDs, and that it is generally well-tolerated. These data were presented at the 62nd annual meeting of the American Epilepsy Society in Seattle.

"These data show that Vimpat(R) may help fill a considerable treatment gap as an add-on therapy for people living with epilepsy whose partial onset seizures are not controlled," said Steve Chung, director of clinical epilepsy research at Barrow Neurological Institute in Phoenix and a lead investigator for the Vimpat(R) clinical trial program. "In general, patients who participated in these trials had lived with epilepsy for an average of over 20 years and had not found seizure control despite trying multiple AEDs. Yet, Vimpat(R) provided significant seizure reduction, compared to placebo, when added to their existing treatment regimen."

The U.S. Food and Drug Administration (FDA) approved Vimpat(R) in October 2008 for use as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older. Vimpat(R) has a novel mechanism of action that is different from all currently available AEDs. The drug will be available in U.S. pharmacies in the first quarter of 2009.

Trials Conducted in Challenging Patient Population

All four analyses evaluated pooled data from one phase II and two phase III multi-center, fixed dose, randomized, double-blind, placebo-controlled clinical trials, evaluating Vimpat(R) as adjunctive therapy. The studies and treatment arms included:


'/>"/>
SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... , July 24, 2014  Now available is a ... Rehealth Regenerative Therapies , located in ... physically active people a new health option: stem ... of age, countless patients suffer from joint and muscle ... as muscle tears, torn rotator cuff, tennis elbow, and ...
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... Distinguished Professor of Engineering at the University of ... solve problems in energy engineering, environmental sustainability and ... zeolites, porous rock with a well-defined, crystalline structure. ... so precisely decided that zeolites can separate molecules ... an angstrom (one-tenth of a nanometer), making them ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2University of Delaware researcher describes new approach for creating organic zeolites 2
... , , WATERTOWN, Mass., Sept. 10 ... breakthrough synthetic chemistry technology announced today that it will ... on the synthesis and antibacterial activity of analogs from ... at the 49th Interscience Conference on Antimicrobial Agents and ...
... STOCKHOLM, September 10 Pergamum AB has announced ... wound healing interests, and create a broad-based therapeutic ... The Pergamum product pipeline consists of five ... Indications covered within the,portfolio include improved wound healing ...
... , , , ... Inc. (PTC) today announced the initiation of a Phase 3 ... in patients with nonsense mutation cystic fibrosis (nmCF). Patients ... conductance regulator (CFTR) protein, a chloride channel necessary for normal ...
Cached Biology Technology:Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6
(Date:7/24/2014)... vision specialist at The University of Texas Health Science ... a grant to help Harris County residents whose vision ... , Even with corrective lenses, many people with low ... a variety of low vision devices, such as telescopes, ... loss. , Iyer is using the three-year, $164,645 SightFirst ...
(Date:7/24/2014)... The Atlantic Forest is a hotspot of biodiversity and ... (frogs, tree-frogs, and toads) in the world. However, current ... past few years has been an increase in the ... with the advance of molecular techniques and availability of ... extensive number of samples for molecular and morphological analysis, ...
(Date:7/24/2014)... N.J. A yearlong study funded by the New ... Edward J. Bloustein School of Planning and Public Policy ... in Sandy-affected towns are skeptical about the likelihood of ... survey respondents, 45 percent indicated they were "pessimistic" or ... by Superstorm Sandy would be rebuilt better than they ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2A tiny new species of frog from Brazil with a heroic name 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... China, September 12, 2013BGI Tech Solutions Co., LTD, ... largest genomics research organization, and South Texas Accelerated ... collaborating on the San Antonio 1000 Cancer Genome ... link genetic alterations that underlie different cancers to ...
... Society of America (ESA) is proud to announce ... Grants. These travel grants, which will help entomology ... in Austin this November are funded by ... Plant-Associated Insects and Nematodes. The grants were created ...
... A tiny number of Asian carp could establish a ... to new research from the University of Waterloo. , Published ... from Professor Kim Cuddington of the Faculty of Science at ... with the introduction of 20 fish into the Great Lakes, ...
Cached Biology News:BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project 2BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project 3Entomological Society of America names winners of 2013 student travel grants 2Entomological Society of America names winners of 2013 student travel grants 3Entomological Society of America names winners of 2013 student travel grants 4Entomological Society of America names winners of 2013 student travel grants 5Entomological Society of America names winners of 2013 student travel grants 6Entomological Society of America names winners of 2013 student travel grants 7Entomological Society of America names winners of 2013 student travel grants 8Tiny number of Asian carp could be big problem for the Great Lakes 2
... Adhesive seal tabs • Reusable, ... can be quickly assembled and disassembled for ... specimens of any thickness with up to ... three chambers per slide. Minimize specimen handling, ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... an aqueous solution that contains a purified ... in a saline solution, pH 6.5 ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ... and stabilizer for biologically active components in ...
Biology Products: